title: Effects of Albunex infusion on left ventricular inflow velocity in dogs.
abstract: This study examined the effects of Albunex (sonicated 5% human serum albumin) infusion on left ventricular inflow velocity by Doppler echocardiography. Left ventricular pressure and left ventricular inflow velocity were recorded simultaneously under eight different conditions in dogs: 1) baseline 1 (control), 2) Albunex 0.2 ml/kg, 3) baseline 2, 4) Albunex 0.5 ml/kg, infusion of dextran 100 ml, 5) baseline 3, 6) Albunex 0.2 ml/kg, 7) baseline 4, and 8) Albunex 0.5 ml/kg. In the normal state (no dextran), Albunex (0.2 ml/kg) caused no hemodynamic changes or inflow velocity changes. In contrast, infusion of Albunex (0.5 ml/kg) caused time velocity integrals of early filling to increase from the baseline (5.51 +/- 1.13 vs 7.19 +/- 1.14 cm, p < 0.05). After dextran infusion (100 ml), Albunex (0.2 ml/kg) caused peak early filling velocity to increase (62.4 +/- 6.9 vs 67.3 +/- 9.4 cm/sec, p < 0.05), and infusion of Albunex (0.5 ml/kg) also caused peak early filling velocity to increase from baseline (64.6 +/- 8.5 vs 73.7 +/- 14.5 cm/sec, p < 0.05). Infusion of Albunex (0.5 ml/kg) after dextran infusion caused increases in left ventricular pressure at the mitral valve opening (12.7 +/- 3.1 vs 15.2 +/- 3.3 mmHg, p < 0.05) and in left atrial driving force (13.5 +/- 3.6 vs 16.7 +/- 5.9 mmHg, p < 0.05). Clinicians should be cautious about using Albunex at doses of greater than 0.2 ml/kg when evaluating the pressure gradient of the left ventricle in patients with elevated left ventricular diastolic pressure. In patients with normal hemodynamics, Albunex infusion at doses of less than 0.2 ml/kg apparently did not affect the velocity measurement.
authors.affiliation: Second Department of Internal Medicine, Gifu University School of Medicine.
authors.forename: M
authors.initials: M
authors.lastname: Tomita
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: R
authors.initials: R
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Miwa
authors.forename: K
authors.initials: K
authors.lastname: Kagawa
authors.forename: T
authors.initials: T
authors.lastname: Noda
authors.forename: K
authors.initials: K
authors.lastname: Nishigaki
authors.forename: S
authors.initials: S
authors.lastname: Hirakawa
authors.forename: H
authors.initials: H
authors.lastname: Fujiwara
mesh_terms: D000418:Albumins / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects; D003287:Contrast Media / Q000008:administration & dosage / Q000494:pharmacology*; D004285:Dogs; D015150:Echocardiography, Doppler; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D007262:Infusions, Intravenous; D008297:Male; D016277:Ventricular Function, Left / Q000187:drug effects*; D017725:Ventricular Pressure / Q000187:drug effects
chemical_list: D000418:Albumins; C060687:Albunex; D003287:Contrast Media